Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunocore Holdings Plc ADR
(NQ:
IMCR
)
31.21
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
100
Open
31.21
Bid (Size)
25.00 (3)
Ask (Size)
32.50 (1)
Prev. Close
31.21
Today's Range
31.21 - 31.21
52wk Range
29.76 - 76.98
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
September 17, 2024
Via
Benzinga
Analyst Expectations For Immunocore Hldgs's Future
September 17, 2024
Via
Benzinga
Performance
YTD
-56.43%
-56.43%
1 Month
-13.50%
-13.50%
3 Month
-10.32%
-10.32%
6 Month
-50.83%
-50.83%
1 Year
-35.01%
-35.01%
More News
Read More
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
September 14, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to present at the 2024 Cantor Global Healthcare Conference
September 12, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces transition of Chief Financial Officer
August 29, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
The Latest Analyst Ratings For Immunocore Hldgs
August 28, 2024
Via
Benzinga
Deep Dive Into Immunocore Hldgs Stock: Analyst Perspectives (9 Ratings)
August 09, 2024
Via
Benzinga
Immunocore reports second quarter financial results and provides a business update
August 08, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
3 Small-Cap Stocks with Significant Growth Potential
August 06, 2024
Via
InvestorPlace
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
August 01, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Peeling Back The Layers: Exploring Immunocore Hldgs Through Analyst Insights
July 10, 2024
Via
Benzinga
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
June 18, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Analyst Expectations For Immunocore Hldgs's Future
May 24, 2024
Via
Benzinga
Where Immunocore Hldgs Stands With Analysts
April 29, 2024
Via
Benzinga
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 03, 2024
Via
Benzinga
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
June 01, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
April 11, 2024
Via
Benzinga
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 31, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to present at the Jefferies Global Healthcare Conference
May 30, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 29, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
Immunocore reports first quarter financial results and provides a business update
May 08, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore announces upcoming presentation and posters at ASCO 2024
April 24, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore to present at upcoming investor conferences
April 04, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.